Psychopharmacology and Psychiatry Updates CBD in Psychiatry: Promise or Hype?
11 snips
Oct 23, 2024 David Mischoulon, a prominent psychiatrist at Massachusetts General Hospital and Harvard Medical School, delves into the intriguing world of Cannabidiol (CBD) and its psychiatric applications. He discusses its potential benefits for disorders like social anxiety and schizophrenia, highlighting the importance of scientific evidence over hype. Mischoulon emphasizes cautious usage, the mechanisms behind CBD, and real-world case studies demonstrating its therapeutic effects. Is CBD the future of mental health treatment or just a trend?
AI Snips
Chapters
Transcript
Episode notes
CBD Overview
- CBD, a non-psychoactive cannabinoid, is available in various forms like oils, capsules, and dried cannabis.
- It's approved for certain medical conditions in some countries, including epilepsy in the U.S.
CBD and THC Caution
- Exercise caution with CBD formulations containing high THC levels.
- This is especially important for young people or those with anxiety or psychotic disorders.
CBD Dosing and Monitoring
- Start with low CBD doses (200-800mg) and titrate gradually ("start low and go slow").
- Regularly assess patients for adverse effects.